AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2024
Jan 4, 2024
31523_dirs_2024-01-04_2cc063b2-0a86-49e0-b365-aced1938d431.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2024-01-02
Reporting Person: Rosenberg Ellen (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-02 | Common Stock | M | 30000 | $5.16 | Acquired | 372285 | Direct |
| 2024-01-02 | Common Stock | S | 30000 | $14.2073 | Disposed | 342285 | Direct |
| 2024-01-02 | Common Stock | A | 63131 | $0.0 | Acquired | 405416 | Direct |
| 2024-01-02 | Common Stock | F | 6985 | $14.24 | Disposed | 398431 | Direct |
| 2024-01-03 | Common Stock | F | 15397 | $13.53 | Disposed | 383034 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-02 | Stock Options (right to buy) | $5.16 | M | 30000 | Disposed | 2026-02-08 | Common Stock (30000) | Direct |
| 2024-01-02 | Stock Options (right to buy) | $14.24 | A | 108980 | Acquired | 2034-01-02 | Common Stock (108980) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 15000 | Indirect |
Footnotes
F1: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.00 to $14.35 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: Granted in the form of Restricted Stock Units ("RSUs"), these RSUs will vest in four equal annual installments beginning on January 2, 2025 and shall be payable in common stock. One (1) RSU is the equivalent of one (1) share of Amicus common stock.
F3: All of the options were fully vested and exercisable as of the transaction date.
F4: These options vest and become exercisable in a series of installments over a four year period with 25% vesting one year after the date of grant and the remaining 75% vesting ratably each month thereafter.